Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ubiquinone Q1 is a synthetic analog of coenzyme Q (ubiquinones), specifically with a single isoprenoid unit in its side chain. It belongs to the class of organic compounds known as ubiquinones or coenzymes Q. While the most common form in humans is coenzyme Q10 (ubiquinone-10), ubiquinone Q1 has been used primarily as an experimental compound and research tool rather than for clinical supplementation or therapy. Like other ubiquinones, it acts as an electron carrier within the mitochondrial electron transport chain and possesses antioxidant properties. However, due to its shorter side chain compared to natural forms like coenzyme Q10 or coenzyme Q9 (the main forms in mammals), it is not widely used therapeutically and does not have established indications for human disease[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ubiquinone q1.